With the rising cost, risk and complexity of R&D, it has become increasingly difficult for life science companies to commercialise medical innovations, informed Dr Adam Hill, UK Government Sector Specialist for Medical Technology and Healthcare.
Speaking at the Going Global Through the UK Seminar in Bangalore, Dr Hill said that the UK government has introduced a suit of fiscal and funding measures to stimulate innovation and growth for business of all sizes. The seminar jointly organised by the UK Trade & Investment (UKTI) in association with BioSpectrum, CEO Council and The Indus Entrepreneur (TiE) Bangalore was held on Wednesday, July 31, 2013.
Attended by around 50 delegates from healthcare industry and allied services the seminar was first in a series of events to facilitate Indian companies to invest in UK life science arena.
The seminar addressed the Indian life sciences companies who are interested in expanding their business base in the UK and wanted to know more about the business opportunities at UK.
Speaking about the event Dr Prasad Rao, CEO, Lablinks said, “Such events are interesting and provide information and guidance to companies who wish to expand business beyond Indian markets.”
Prashant Sabeshan, Partner, Majumdar & Partners, corporate lawyers said, “The talk mostly revolved around outbound business. The inbound aspect was missing.”
Dr Hill discussed UK Government’s Life Science Policy, the opportunity and marketplace , access to the UK at every stage of the medical technology development pathway, and the new NHS structure.
UK Trade & Investment is the national government agency that offers free support and independent advice to foreign companies looking to invest or locate in the UK.
Gita Krishnankutty, Senior Trade & Investment Adviser, UK Trade & Investment was also present at the event.
EH News Bureau
- Advertisement -
